For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
No place for separate primary care scrutiny as Clark announces major sector review (Updated)
+News
No place for separate primary care scrutiny as Clark announces major sector review (Updated)
Tuesday 29 May 2018, 03:41 PM

David Clark at the NZMA earlier this year
Ths article has been updated to include comment from Tim Malloy, Jeff Lowe and Allan Moffitt
The expected Government review of primary care funding appears to have been superseded by a much wider-ranging review of the health system announced
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.